A kojic acid and tranexamic acid lip serum sold in the United States as a cosmetic does not require FDA pre-market approval, provided it is positioned purely as a cosmetic product (i.e., making only cosmetic claims like 'brightens the appearance of lip discoloration' rather than drug claims like 'treats melasma' or 'reduces hyperpigmentation caused by hormonal changes').
However, 'no pre-market approval' is not the same as 'no FDA obligations.' The Modernization of Cosmetics Regulation Act (MoCRA), enacted in December 2022, introduced the most significant new requirements for US cosmetics in decades. As of 2024, MoCRA requires: (1) facility registration for any establishment that manufactures or processes cosmetic products for US distribution; (2) product listing with the FDA for each cosmetic product, including the complete ingredient list; (3) serious adverse event reporting within 15 business days of receiving a report; and (4) maintenance of records sufficient to conduct a safety assessment.
For a lip serum specifically, the safety assessment is critical. Lips are a semi-mucous membrane, oral exposure is likely, and the FDA scrutinizes leave-on lip products more closely than rinse-off skin products. A cosmetic safety assessor (typically a toxicologist) reviews each ingredient at its formulated concentration and confirms the product is safe for the intended use. This is not legally mandatory in the US yet in the same explicit way it is in the EU, but most responsible manufacturers require it, and major US retailers (Ulta, Sephora, Target) now require a safety substantiation file as part of their vendor onboarding.
For kojic acid specifically: it is not on the FDA's prohibited or restricted ingredient list, so there is no concentration limit under US law for cosmetic use. However, if you market to consumers in the EU, kojic acid in leave-on face and lip products is capped at 1% w/w per the current SCCS opinion, and the ingredient requires notification under the EU Cosmetic Products Regulation. Canada requires pre-notification under the Cosmetic Regulations for products containing kojic acid.
Transexamic acid has no US or EU cosmetic restriction at typical leave-on concentrations (2–5%), though positioning language remains the dividing line between cosmetic and drug status.
Mistake to avoid: Using drug-adjacent claim language on the label or in social media — 'treats,' 'cures,' 'corrects a skin condition' — which triggers drug classification and requires NDA or OTC monograph compliance. Stick to cosmetic appearance claims and you remain in the lower-burden regulatory lane.
Ingredients in this answer: Tranexamic Acid · Kojic Acid
Read the full guide on Private Label Tranexamic Acid Kojic Acid Lip Serum Manufacturer →